Radošević, Draginja

Link to this page

Authority KeyName Variants
orcid::0000-0002-3284-7201
  • Radošević, Draginja (3)
Projects

Author's Bibliography

In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine

Matejin, Stanislava; Bukreyeva, Natalya; Radošević, Draginja; Senćanski, Milan V.; Mantlo, Emily; Veljković, Veljko; Glišić, Sanja; Paessler, Slobodan

(2020)

TY  - JOUR
AU  - Matejin, Stanislava
AU  - Bukreyeva, Natalya
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Mantlo, Emily
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9036
AB  - Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.
T2  - Antiviral Therapy
T1  - In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine
VL  - 24
IS  - 8
SP  - 589
EP  - 593
DO  - 10.3851/IMP3348
ER  - 
@article{
author = "Matejin, Stanislava and Bukreyeva, Natalya and Radošević, Draginja and Senćanski, Milan V. and Mantlo, Emily and Veljković, Veljko and Glišić, Sanja and Paessler, Slobodan",
year = "2020",
abstract = "Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.",
journal = "Antiviral Therapy",
title = "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine",
volume = "24",
number = "8",
pages = "589-593",
doi = "10.3851/IMP3348"
}
Matejin, S., Bukreyeva, N., Radošević, D., Senćanski, M. V., Mantlo, E., Veljković, V., Glišić, S.,& Paessler, S.. (2020). In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine. in Antiviral Therapy, 24(8), 589-593.
https://doi.org/10.3851/IMP3348
Matejin S, Bukreyeva N, Radošević D, Senćanski MV, Mantlo E, Veljković V, Glišić S, Paessler S. In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine. in Antiviral Therapy. 2020;24(8):589-593.
doi:10.3851/IMP3348 .
Matejin, Stanislava, Bukreyeva, Natalya, Radošević, Draginja, Senćanski, Milan V., Mantlo, Emily, Veljković, Veljko, Glišić, Sanja, Paessler, Slobodan, "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine" in Antiviral Therapy, 24, no. 8 (2020):589-593,
https://doi.org/10.3851/IMP3348 . .
1
1

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors

Radošević, Draginja; Senćanski, Milan V.; Perović, Vladimir R.; Veljković, Nevena V.; Prljić, Jelena; Veljković, Veljko; Mantlo, Emily; Bukreyeva, Natalya; Paessler, Slobodan; Glišić, Sanja

(2019)

TY  - JOUR
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
AU  - Mantlo, Emily
AU  - Bukreyeva, Natalya
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2019
UR  - https://www.frontiersin.org/article/10.3389/fcimb.2019.00067/full
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8163
AB  - Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.
T2  - Frontiers in Cellular and Infection Microbiology
T1  - Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors
VL  - 9
SP  - 67
DO  - 10.3389/fcimb.2019.00067
ER  - 
@article{
author = "Radošević, Draginja and Senćanski, Milan V. and Perović, Vladimir R. and Veljković, Nevena V. and Prljić, Jelena and Veljković, Veljko and Mantlo, Emily and Bukreyeva, Natalya and Paessler, Slobodan and Glišić, Sanja",
year = "2019",
abstract = "Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.",
journal = "Frontiers in Cellular and Infection Microbiology",
title = "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors",
volume = "9",
pages = "67",
doi = "10.3389/fcimb.2019.00067"
}
Radošević, D., Senćanski, M. V., Perović, V. R., Veljković, N. V., Prljić, J., Veljković, V., Mantlo, E., Bukreyeva, N., Paessler, S.,& Glišić, S.. (2019). Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology, 9, 67.
https://doi.org/10.3389/fcimb.2019.00067
Radošević D, Senćanski MV, Perović VR, Veljković NV, Prljić J, Veljković V, Mantlo E, Bukreyeva N, Paessler S, Glišić S. Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology. 2019;9:67.
doi:10.3389/fcimb.2019.00067 .
Radošević, Draginja, Senćanski, Milan V., Perović, Vladimir R., Veljković, Nevena V., Prljić, Jelena, Veljković, Veljko, Mantlo, Emily, Bukreyeva, Natalya, Paessler, Slobodan, Glišić, Sanja, "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors" in Frontiers in Cellular and Infection Microbiology, 9 (2019):67,
https://doi.org/10.3389/fcimb.2019.00067 . .
1
19
7
18

Natural Products as Promising Therapeutics for Treatment of Influenza Disease

Senćanski, Milan V.; Radošević, Draginja; Perović, Vladimir R.; Gemović, Branislava S.; Stanojevic, Maja; Veljković, Nevena V.; Glišić, Sanja

(2015)

TY  - JOUR
AU  - Senćanski, Milan V.
AU  - Radošević, Draginja
AU  - Perović, Vladimir R.
AU  - Gemović, Branislava S.
AU  - Stanojevic, Maja
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/806
AB  - The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
T2  - Current Pharmaceutical Design
T1  - Natural Products as Promising Therapeutics for Treatment of Influenza Disease
VL  - 21
IS  - 38
SP  - 5573
EP  - 5588
DO  - 10.2174/1381612821666151002113426
ER  - 
@article{
author = "Senćanski, Milan V. and Radošević, Draginja and Perović, Vladimir R. and Gemović, Branislava S. and Stanojevic, Maja and Veljković, Nevena V. and Glišić, Sanja",
year = "2015",
abstract = "The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.",
journal = "Current Pharmaceutical Design",
title = "Natural Products as Promising Therapeutics for Treatment of Influenza Disease",
volume = "21",
number = "38",
pages = "5573-5588",
doi = "10.2174/1381612821666151002113426"
}
Senćanski, M. V., Radošević, D., Perović, V. R., Gemović, B. S., Stanojevic, M., Veljković, N. V.,& Glišić, S.. (2015). Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design, 21(38), 5573-5588.
https://doi.org/10.2174/1381612821666151002113426
Senćanski MV, Radošević D, Perović VR, Gemović BS, Stanojevic M, Veljković NV, Glišić S. Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design. 2015;21(38):5573-5588.
doi:10.2174/1381612821666151002113426 .
Senćanski, Milan V., Radošević, Draginja, Perović, Vladimir R., Gemović, Branislava S., Stanojevic, Maja, Veljković, Nevena V., Glišić, Sanja, "Natural Products as Promising Therapeutics for Treatment of Influenza Disease" in Current Pharmaceutical Design, 21, no. 38 (2015):5573-5588,
https://doi.org/10.2174/1381612821666151002113426 . .
4
26
19
28